aymond, D. D. et al. Conserved epitope on inﬂuenza-virus hemagglutinin head 45. Pincus, S. et al. Release and stability testing program
eﬁned by a vaccine-induced antibody. Proc. Natl Acad. Sci. USA 115, 168–173 ticle vaccine. Biopharm. Int 23 Suppl 10, 26–34 (201
2018). 46. Fernandes, F. et al. Insect cells as a production pla
autto, G. A., Kirchenbaum, G. A. & Ross, T. M. Towards a universal inﬂuenza particles. Expert Rev. Vaccines 12, 225–236 (2013).
accine: different approaches for one goal. Virol. J. 15, 17 (2018). 47. Inﬂuenza vaccine strategies for broad global acces
achbagauer, R. et al. A chimeric hemagglutinin-based universal inﬂuenza virus azureedge.net/media/documents/VAC_inﬂ_publ_rpt_
accine approach induces broad and long-lasting immunity in a randomized, 2021.
lacebo-controlled phase I trial. Nat. Med. 27, 106–114 (2021). 48. European Medicines Agency. Assessment report.
renstein, W. A. & Schaffner, W. Lessons learned: role of inﬂuenza vaccine pro- EMEA/H/C/005159/0000. Available at https://www.em
uction, distribution, supply, and demand–what it means for the provider. Am. J. assessment-report/supemtek-epar-public-assessment-r
Med. 121, S22–S27 (2008). February 2021.
elberbaum, R. S. The baculovirus expression vector system: a commercial 49. Health Canada. Register of Innovative Drugs [Updat
manufacturing platform for viral vaccines and gene therapy vectors. Biotechnol. J. from https://www.canada.ca/en/health-canada/serv
0, 702–714 (2015). drug-products/applications-submissions/register-inno
ox, M. M. & Hashimoto, Y. A fast track inﬂuenza virus vaccine produced in insect sed 19 April 2021.
ells. J. Invertebr. Pathol. 107, S31–S41 (2011). 50. Taubenberger, J. K. Inﬂuenza virus hemagglutinin c
aymond, D. D. et al. Inﬂuenza immunization elicits antibodies speciﬁc for an laughing matter. Proc. Natl Acad. Sci. USA 95, 9713–
gg-adapted vaccine strain. Nat. Med. 22, 1465–1469 (2016). 51. Stieneke-Gröber, A. et al. Inﬂuenza virus hemagglutin
kowronski, D. M. et al. Low 2012-13 inﬂuenza vaccine effectiveness associated site is activated by furin, a subtilisin-like endoprotea
ith mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in (1992). PMC556715.
irculating viruses. PLoS ONE 9, e92153 (2014). 52. Chen, J. et al. Structure of the hemagglutinin precu
ost, S. J. et al. Contemporary H3N2 inﬂuenza viruses have a glycosylation site minant of inﬂuenza pathogenicity and the origin of t
hat alters binding of antibodies elicited by egg-adapted vaccine strains. Proc. 95, 409–417 (1998).
atl Acad. Sci. USA 114, 12578–12583 (2017). 53. Luczo, J. M. et al. Molecular pathogenesis of H5 hig
lannery, B. et al. Interim estimates of 2016-17 seasonal inﬂuenza vaccine enza: the role of the haemagglutinin cleavage site
ffectiveness - United States, February 2017. MMWR Morb. Mortal. Wkly Rep. 66, 406–430 (2015).
67–171 (2017). 54. Boonstra, S. et al. Hemagglutinin-mediated memb
hu, Y. & McCauley, J. GISAID: Global initiative on sharing all inﬂuenza data - from perspective. Annu Rev. Biophys. 47, 153–173 (2018).
ision to reality. Euro surveillance: bulletin Europeen sur les maladies transmis- 55. McCraw, D. M., Gallagher, J. R. & Harris, A. K. Characte
ibles = European communicable disease bulletin 22, https://doi.org/10.2807/ hemagglutinin complexes by cryo-electron micros
560-7917.Es.2017.22.13.30494 (2017). reveals structural polymorphisms. Clin. Vaccin. Immu
ong, L. et al. Efﬁcacious recombinant inﬂuenza vaccines produced by high yield 56. Kost, T. A. & Condreay, J. P. Recombinant baculovirus
acterial expression: a solution to global pandemic and seasonal needs. PLoS insect and mammalian cells. Curr. Opin. Biotechnol. 1
NE 3, e2257 (2008). 57. Webster, R. G., Brown, L. E. & Jackson, D. C. Change
ussey, L. et al. Phase 1 safety and immunogenicity study of a quadrivalent hemagglutinin molecule of H3 inﬂuenza virus at acidi
easonal ﬂu vaccine comprising recombinant hemagglutinin-ﬂagellin fusion (1983).
roteins. Open Forum Infect. Dis. 3, ofw015 (2016). 58. Lee, P. S. & Wilson, I. A. Structural characterization of
guilar-Yanez, J. M. et al. An inﬂuenza A/H1N1/2009 hemagglutinin vaccine broadly cross-reactive antibodies. Curr. Top. Microbi
roduced in Escherichia coli. PLoS ONE 5, e11694 (2010). (2015).
aczynska, V. Inﬂuenza virus hemagglutinin as a vaccine antigen produced in 59. Turner, H. L. et al. Potent anti-inﬂuenza H7 human m
acteria. Acta Biochim Pol. 61, 561–572 (2014). separation of hemagglutinin receptor-binding hea
avis, A. R. et al. Immune response to human inﬂuenza virus hemagglutinin e3000139 (2019).
xpressed in Escherichia coli. Gene 21, 273–284 (1983). 60. Khurana, S. et al. Repeat vaccination reduces antibod
osales-Mendoza, S. et al. What does plant-based vaccine technology offer to the different inﬂuenza vaccine platforms in humans. Nat
ght against COVID-19? Vaccines 8, 183 (2020). 61. Ekiert, D. C. et al. Antibody recognition of a highly
illet, S. et al. A plant-derived quadrivalent virus like particle inﬂuenza vaccine epitope. Science 324, 246–251 (2009).
nduces cross-reactive antibody and T cell response in healthy adults. Clin. 62. Kallewaard, N. L. et al. Structure and function analysis
mmunol. 168, 72–87 (2016). all inﬂuenza A subtypes. Cell 166, 596–608 (2016).
illet, S. et al. Immunogenicity and safety of a quadrivalent plant-derived virus 63. Benhaim, M. A. et al. Structural monitoring of a tr
ke particle inﬂuenza vaccine candidate-two randomized Phase II clinical trials in hemagglutinin fusion machinery on inﬂuenza virions.
8 to 49 and >/=50 years old adults. PLoS ONE 14, e0216533 (2019). 64. Portnoff, A. D. et al. Inﬂuenza hemagglutinin nanopa
Ward, B. J. et al. Efﬁcacy, immunogenicity, and safety of a plant-derived, quad- neutralizing antibodies against structurally distinct do
ivalent, virus-like particle inﬂuenza vaccine in adults (18-64 years) and older 8, 99 (2020).
dults (>/=65 years): two multicentre, randomised phase 3 trials. Lancet 396, 65. Richards, K. A. et al. Recombinant HA-based vaccine
491–1503 (2020). unit vaccines in elicitation of inﬂuenza-speciﬁc CD
Won, S. Y. et al. Characterization of the innate stimulatory capacity of plant- dependent antibody responses in humans. NPJ Vacc
erived virus-like particles bearing inﬂuenza hemagglutinin. Vaccine 36, 66. Tay, T. et al. Investigation into alternative testing met
028–8038 (2018). tion of inﬂuenza virus vaccine. Hum. Vaccines Immun
andey, A. et al. Impact of preexisting adenovirus vector immunity on immu- 67. Gallagher, J. R. et al. Characterization of hemagglu
ogenicity and protection conferred with an adenovirus-based H5N1 inﬂuenza virus and within vaccines using electron microsco
accine. PLoS ONE 7, e33428–e33428 (2012). 10.3390/vaccines6020031 (2018).
ayedahmed, E. E. et al. Adenoviral vector-based vaccine platforms for devel- 68. Public Health Agency of Canada. Oculo-respiratory sy
ping the next generation of inﬂuenza vaccines. Vaccines 8, 574 (2020). vaccination: review of post-marketing surveillance t
iang, K. et al. Progress on adenovirus-vectored universal inﬂuenza vaccines. sons in Canada. Can. Commun. Dis. Rep. 31, 217–225
um. Vaccin Immunother. 11, 1209–1222 (2015). 69. Choudhri, Y. & Walop, W. Inﬂuenza vaccine-associate
hen, J. R. et al. Better inﬂuenza vaccines: an industry perspective. J. Biomed. Sci. passive surveillance, Canada 2001-2002. Can. Com
7, 33 (2020). (2002).
eport to the president on reengeneering the inﬂuenza vaccine production 70. Babiuk, S. et al. Aggregate content inﬂuences the Th
nterprise to meet the challenges of pandemic inﬂuenza. Available at https:// inﬂuenza vaccine: evidence from a mouse model. J. M
bamawhitehouse.archives.gov/sites/default/ﬁles/microsites/ostp/PCAST- 71. Wei, C. J. et al. Cross-neutralization of 1918 and 20
nﬂuenza-Vaccinology-Report.pdf. Accessed August 2021. glycans in viral evolution and vaccine design. Sci. Tr
ópez-Macías, C. et al. Safety and immunogenicity of a virus-like particle pan- 72. An, Y. et al. N-glycosylation of seasonal inﬂuenz
emic inﬂuenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo- implication for potency testing and immune proces
ontrolled trial of adults in Mexico. Vaccine 29, 7826–7834 (2011). 10.1128/JVI.01693-18 (2019).